Everolimus is an oral mTOR inhibitor which has been approved for use in post-menopausal women with HR-positive breast cancer; it is also approved for used in other cancers including renal cell carcinoma, neuroendocrine tumors of the pancreas and subependymal giant cell astrocytomas. Here, MTOR is linked to cancer.